A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension [EXTENSION OF 700243262]

Trial Profile

A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension [EXTENSION OF 700243262]

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Bosentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Registrational
  • Acronyms FUTURE 3 Ext
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 01 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Apr 2014 New trial record
    • 28 Feb 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top